Abstract
Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.
Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Incretin Based Therapies: Bone Protective Effects
Volume: 13 Issue: 4
Author(s): Marlene Chakhtoura and Sami T. Azar
Affiliation:
Keywords: Dipeptidyl peptidase-4 inhibitors, glucagon like peptide -1 agonists, incretin therapy, osteoporosis, type 2 diabetes mellitus.
Abstract: Type 2 Diabetes Mellitus (T2D) and osteoporosis have been found recently to be tightly correlated. In fact, T2D can result in bone loss through different mechanisms resulting in alteration of bone matrix and inhibition of bone formation. Fracture risk also increases significantly. New antidiabetic agents, dipeptidyl peptidase-4 inhibitors and glucagon like peptide -1 agonists have shown promise in many fields beyond glycemic control. Benefits on the skeletal system are multiple through direct stimulation of osteoblasts, inhibition of advanced glycation end products and inhibition of bone resorption. However, clinical evidence in humans is still not enough to allow definitive conclusions.
Export Options
About this article
Cite this article as:
Chakhtoura Marlene and Azar T. Sami, Incretin Based Therapies: Bone Protective Effects, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (4) . https://dx.doi.org/10.2174/18715303113136660046
DOI https://dx.doi.org/10.2174/18715303113136660046 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
Current Drug Metabolism Role of Oxidative Stress in Polycystic Ovary Syndrome
Current Women`s Health Reviews Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology High Sensitivity C-reactive Protein and Cardiovascular Risk Prediction
Current Pharmaceutical Analysis Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery Obesity in the Childhood: A Link to Adult Hypertension
Current Pharmaceutical Design Fresh or Frozen Embryo Selection in Embryo Transfer: Live Birth Rates and Obstetric and Fetal/Neonatal Results
Current Women`s Health Reviews Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Long Noncoding RNAs as Diagnostic and Therapeutic Targets for Ischemic Stroke
Current Pharmaceutical Design A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Medical Treatment of Hirsutism in Women
Current Medicinal Chemistry The GLUTs Family - Lessons from Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Industrial Applications of Thermostable Enzymes from Extremophilic Microorganisms
Current Biochemical Engineering (Discontinued) Antihypertensive Efficacy and Tolerability of Aliskiren/Amlodipine Single- Pill Combinations in Patients with an Inadequate Response to Aliskiren Monotherapy¥
Current Vascular Pharmacology Reverse Ayurvedic Pharmacology of Ashwagandha as an Adaptogenic Anti-Diabetic Plant: A Pilot Study
Current Traditional Medicine The Molecular Targets of Swertiamarin and its Derivatives Confer Anti- Diabetic and Anti-Hyperlipidemic Effects
Current Drug Targets Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology